title: [Pluripotent stem cells as a source for T cell research and clinical application].
abstract: Recently, promising clinical outcomes of cancer immunotherapy including administration of an anti PD-1 antibody targeting for T cell reactivation has gained particular attention worldwide. Adoptive cell therapy with tumor infiltrating lymphocytes and TCR/CAR (Chimeric Antigen Receptor) transgenic T cells are also under development. Although it has become clearer that the efficacy of adoptive cell therapy correlate with the quality of infusing T cells, antigen specific T cells in patients with chronic infection and cancer have been exhausted. We have succeeded to generate rejuvenated antigen specific T cells by reprogramming to pluripotency and differentiation. In this article, we introduce fundamentals of this technology and describe its potential for adoptive cell therapy in the future.
authors.affiliation: Department of Cell Growth and Development, Center for iPS Cell Reserch and Application (CiRA), Kyoto University.
authors.forename: Tatsuki
authors.initials: T
authors.lastname: Ueda
authors.forename: Shin
authors.initials: S
authors.lastname: Kaneko
mesh_terms: D064591:Allografts; D000906:Antibodies / Q000008:administration & dosage; D064592:Autografts; D002454:Cell Differentiation; D065150:Cellular Reprogramming; D000067470:Cellular Reprogramming Techniques / Q000379:methods / Q000639:trends; D000939:Epitopes; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods / Q000639:trends; D057026:Induced Pluripotent Stem Cells; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D011948:Receptors, Antigen, T-Cell; D012038:Regeneration; D013601:T-Lymphocytes / Q000276:immunology / Q000502:physiology
chemical_list: D000906:Antibodies; D000939:Epitopes; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D011948:Receptors, Antigen, T-Cell